
Beacon's emerging XLRP gene therapy improves low-light vision in phase 3 trial
22.9.2026
0:00
4:26
Beacon Therapeutics reported positive results from the Phase 3 pivotal trial of laru-zova, its potential gene therapy treatment for X-linked retinitis pigmentosa. A significant proportion of patients improved dim-light vision by 15 or more letters after treatment with either high or low doses of laru-zova compared to the group that was not treated, according to preliminary results from the VISTA clinical trial. Beacon plans to begin seeking FDA approval later this year. If approved, this would be the first treatment available for XLRP, one of the more severe forms of retinitis pigmentosa that predominantly affects males.
Flere episoder fra "Foundation Fighting Blindness"



Gå ikke glip af nogen episoder af “Foundation Fighting Blindness” - abonnér på podcasten med gratisapp GetPodcast.








